Fallberichte

Thomas Brinkmeier, Rudolf Herbst(Helios Klinikum Erfurt), Bernd Angelkort, Peter J. Frosch(Ospedale Regionale di Bellinzona e Valli)
JDDG Journal der Deutschen Dermatologischen Gesellschaft
March 1, 2003
10.1046/j.1610-0387.2003.02037.x
Cited by 4

Related Papers

Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial
|The Lancet Oncology|2016|704
Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma
|PLoS ONE|2015|292
Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node
|Journal of Clinical Oncology|2019|254
Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial
|The Lancet|2020|242
Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition
|European Journal of Cancer|2017|203